高血压肾损害 中国就医指南

Hypertensive nephropathy, also known as hypertensive kidney disease or chronic hypertensive nephrosclerosis, is a progressive form of chronic kidney disease (CKD) resulting from long-standing, uncontrolled arterial hypertension. It is characterized by structural and functional damage to the renal microvasculature—particularly arterioles and glomeruli—leading to glomerulosclerosis, tubulointerstitial fibrosis, and eventual decline in glomerular filtration rate (GFR). Pathogenesis centers on hemodynamic stress: sustained high systemic pressure causes endothelial injury, vascular smooth muscle hypertrophy, hyaline arteriolosclerosis, and ischemic glomerular damage. Over time, this triggers inflammatory cascades, oxidative stress, renin-angiotensin-aldosterone system (RAAS) overactivation, and profibrotic signaling (e.g., TGF-β), culminating in irreversible scarring. Unlike acute hypertensive emergencies, hypertensive nephropathy develops insidiously over years or decades, often without early symptoms. Epidemiologically, it accounts for approximately 10–25% of end-stage kidney disease (ESKD) cases globally and is among the top three causes of CKD in China—especially prevalent in adults aged 50–75 years. Hypertension affects over 270 million adults in China, and roughly 15–20% of those with stage 2+ hypertension develop clinically significant kidney impairment within 10–15 years if untreated. Key modifiable risk factors include persistent systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, poor antihypertensive adherence, diabetes mellitus (which synergistically accelerates renal injury), obesity, smoking, high-sodium diet, and sedentary lifestyle. Non-modifiable risks include older age, male sex, African or East Asian ancestry, and family history of hypertension or CKD. Quality of life is significantly impaired as disease advances: patients commonly experience fatigue, nocturia, reduced exercise tolerance, sleep disturbances, anxiety about dialysis or transplant, and socioeconomic strain due to treatment burden and work limitations. Early-stage disease may be asymptomatic, delaying diagnosis; later stages bring edema, shortness of breath (from fluid overload), cognitive fog, and increased cardiovascular mortality—making hypertensive nephropathy not only a renal disorder but a major driver of overall morbidity and premature death. Timely detection via routine urinalysis (microalbuminuria), serum creatinine/eGFR monitoring, and renal ultrasound is critical. Management hinges on rigorous blood pressure control (<130/80 mmHg for most CKD patients), RAAS blockade (ACE inhibitors or ARBs), sodium restriction (<2 g/day), and integrated cardiovascular risk reduction.

# 高血压肾损害治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：eGFR ≥60 mL/min/1.73m²、尿蛋白<1g/d、无显著肾萎缩者

• •基础药物治疗（ACEI/ARB+CCB+利尿剂）：年药费 2,400–6,800元（国产至原研）
• •靶器官保护用药（SGLT2抑制剂、MRA）：年药费 4,200–15,600元
• •配套检查：尿微量白蛋白/肌酐比值、eGFR动态监测、肾脏超声、24h尿蛋白定量：860–1,950元/次

二、介入/核心治疗方案

适用人群：难治性高血压合并肾动脉狭窄（影像学证实≥70%狭窄）、RAS相关进展性肾功能下降

• •肾动脉造影+支架置入术（微创介入）：总费用 48,000–92,000元（含DSA术费、支架耗材、住院）
• •术前检查（CTA/MRA+肾功能评估+心超）：3,200–5,800元

三、晚期/并发症专项方案

适用人群：eGFR <15 mL/min/1.73m²、尿毒症期、合并心衰或顽固性水肿

• •维持性血液透析（每周3次）：年均费用 65,000–82,000元（医保报销后自付约12,000–20,000元）
• •肾移植评估及等待期管理：评估费 18,000–26,000元；移植手术总费用（含供体匹配、手术、免疫抑制剂首年） 280,000–360,000元

四、方案快速选择指南

• •预算有限/早期患者：优选国产药物+规范随访（年支出≤8,000元）
• •中等预算/进展期：加用SGLT2i+定期介入评估（年支出12,000–25,000元）
• •晚期/并发症高风险：及时启动透析或移植评估（首年投入≥65,000元）